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The goal of this study was to determine the knowledge and attitudes of transgender 
adolescents regarding fertility and future parenthood. We developed and administered a 
cross-sectional questionnaire to a convenience sample of 23 transgender and gender non-
conforming adolescents (mean age 16.2 ± 2.6) who attended the Yale Pediatric Gender 
Program between October 2016 and August 2017. Our results indicate that transgender 
adolescents have a basic understanding of reproductive health and fertility (mean total 
knowledge score of 3.78 ± 0.80 out of 5). Knowledge scores were significantly higher in 
participants with previous information about gender-affirming hormone therapy (GAH; 
p<0.05), which most commonly came from a physician (65%). When asked about future 
parenthood, most participants favored non-biological over biological parenthood (70% 
vs. 22%). Similar proportions of participants viewed future parenthood as important and 
unimportant (both 30%), but those who reported future parenthood as the least important 
had the greatest level of concern about becoming a parent (p<0.0001). Other common 
concerns included the postponement of GAH to preserve fertility (35%) and the time and 
effort required to have a child (30%). Outcomes did not differ significantly by use of 
pubertal blockers or GAH. In conclusion, transgender adolescents at our university-based 
clinic are overall knowledgeable about reproductive health and fertility and favor non-
biological parenthood. Patient education by providers effectively increases knowledge 
and awareness of transgender-specific fertility topics. Despite this, many still disclose 
concerns and may express these concerns as disinterest in parenthood. This data 
highlights the need for frequent and repeated counseling with every patient about the 
risks for diminished fertility with GAH and options for future parenthood. Doing so will 
enable transgender adolescents to make reproductive-related decisions based on careful 
consideration rather than fear or concern.   
 
Acknowledgements 
First and foremost, I would like to express my sincere gratitude to Drs. Julia Cron, 
Amanda Kallen, and Christy Olezeski. Thank you for trusting me to do this project and 
for your unwavering support of my thesis work and career goals. I am inspired by your 
commitment to your patients and the profession and feel honored to have benefited from 
your extensive personal and professional guidance. I would also like to thank Dr. Anisha 
Patel, Dr. Susan Boulware, Dr. Stuart Weinzimer, Faria Kamal, Wendy Bamatter, Rachel 
Lawton, and everyone at the Yale Gender Program (YGP) who provided feedback and 
support for this survey project. You truly embody what it means to provide inclusive, 
compassionate patient care. Thank you to the patients at the YGP. You are at the heart of 
this project, and I will be forever grateful that you took time to share your thoughts about 
such intimate topics with me. To Fritha Morrison, thank you for spending countless hours 
explaining statistics to me. Maybe one day I will be able to understand it on my own, but 
until then I am grateful to have you. I am also thankful to the Yale Office of Student 
Research for financial support. Deepest thank you to my family and friends—Peter and 
Effie Alphonso, Nicolette and Denby Morrison, Catherine Tomasulo, Aman Shah, and 
Anna Diakun—who have loved and supported me unconditionally throughout this 
journey through medical school. Finally, but by no means least, I sincerely thank my 









































































































List of Abbreviations 
ART assisted reproductive technology 
DSM Diagnostic and Statistical Manual of Mental Disorders 
FP fertility preservation 
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As many as 1.4 million people in the United States identify as transgender, or have a sex 
assigned at birth that is incongruent with the internal gender with which they identify (1). 
In some transgender individuals, this incongruence causes an intense and pervasive sense 
of distress or discomfort known as gender dysphoria. Transgender individuals with 
gender dysphoria are two to four times more likely to have been diagnosed with 
depression, anxiety, and suicidal ideation than the non-gender dysphoric population (2–
4). A large national transgender survey found that 41% of transgender adults have ever 
attempted suicide, over 25 times the 1.6% suicide attempt rate in the general population 
(5). These findings provide a strong impetus to examine the healthcare needs of 
transgender individuals and to provide high-quality, gender-affirming care.  
 At present, the treatment options available for alleviation of gender dysphoria 
include medical therapy and surgery. Transgender individuals may utilize one, both, or 
neither of these options in the course of their transition. Two forms of medical therapy 
used to alleviate gender dysphoria are (1) puberty blocking medication to prevent the 
development of unwanted secondary sex characteristics and (2) masculinizing or 
feminizing hormones to facilitate gender transition. Children as young as age eight who 
are entering puberty and experiencing gender dysphoria may delay puberty through the 
use of gonadotropin-releasing hormone agonists (GnRHa), the most common type of 
puberty blocking medication (6). GnRHa are synthetic hormones that mimic the action of 
naturally occurring GnRH, which stimulates the downstream production of the sex 
hormones estrogen and testosterone with pulsatile administration but suppresses or “shuts 
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down” the production of these hormones with sustained, non-pulsatile administration. 
Older adolescents and adults may seek gender-affirming hormone therapy (GAH)1 
through the masculinizing hormone testosterone or the feminizing hormone 17β-estradiol 
(7). Testosterone facilitates the female-to-male transition by stimulating androgen 
receptors, causing a deepened voice, male pattern facial and body hair development, and 
increased muscle mass (8,9). 17β-estradiol is a form of estrogen which facilitates male-
to-female transition by stimulating estrogen receptors in the testes and breasts, causing 
decreased testicular size and breast growth (8). GAH is typically started after age 16, but 
may be started as early as age 13.5 to 14 in adolescents who are well-established in their 
gender identity (10–12). GAH is the primary medical therapy pursued by transgender 
individuals to attain secondary sex characteristics better aligned with their gender 
identity.  
Gender-affirming surgery includes many options such as gonadectomy—removal 
of the ovaries or testes; hysterectomy—removal of the uterus; chest surgery (‘top 
surgery’)—masculinizing through the removal of breast tissue or feminizing through the 
placement of breast-shaped implants; genital surgery (‘bottom surgery’)—masculinizing  
phalloplasty to create a penis or feminizing vaginoplasty to create a vagina; facial 
feminization surgery to create a feminine facial profile; among others. According to 
guidelines from the World Professional Association for Transgender Health (WPATH), 
transgender individuals older than 18 years who have been on hormonal therapy for at 
least one year may pursue these options (13). However, many transgender men and 
women will seek hormone therapy without plans to undergo surgical intervention (14). 
                                               
1 Formerly referred to as cross-sex hormones or cross-hormone therapy 
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Those who pursue surgery may do so in various amounts, pursuing one or any 
combination of top, bottom, or other type of surgery that best aligns with their gender 
identity.  
While enabling transgender individuals to achieve a desired physical appearance 
and alleviating gender dysphoria, gender-affirming interventions may also have 
deleterious effects on reproduction and fertility (15–17). These adverse effects on 
reproductive health have caused several groups, including WPATH, the Endocrine 
Society, the American Society for Reproductive Medicine, and the University of 
California San Francisco Center of Excellence for Transgender Health, to issue strong 
recommendations that transgender individuals be counseled on the various strategies 
available to preserve fertility prior to transition, and that these options be made readily 
available for those individuals wishing to utilize them (10,13,18,19).  
Early access to fertility preservation (FP) is particularly pertinent for transgender 
adolescents, who are presenting for medical attention at higher rates than previously seen 
(6,11,20–24). Adolescents who undergo FP procedures before transition benefit from (1) 
preservation of fertility prior to the onset of the deleterious reproductive effects of GAH 
detailed above and (2) the avoidance of later interruption of their GAH therapy in order 
to undergo FP. Individuals who have transitioned and wish to become parents or undergo 
FP are advised to stop their GAH, which presents a challenge when cessation of GAH 
risks the return of unwanted sex characteristics and potential exacerbation of gender 
dysphoria (13). Therefore, healthcare providers—in addition to validating adolescents in 
their transgender identity through medical therapy—should ensure that adolescents make 
timely and fully-informed decisions about their future fertility prior to transition. Ideally 
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transgender adolescents and their families will take advantage of reproductive 
technologies when desired and appropriate and avoid potential future distress. However, 
no prior studies to our knowledge have prospectively examined the decision-making 
experiences of transgender adolescents surrounding FP and future parenthood.  
Our study addresses this gap in the literature in several ways. First, the study 
examines transgender adolescents’ baseline knowledge about reproductive health and 
fertility to establish their ability to participate in decision-making in these areas. Second, 
the study characterizes transgender adolescents’ goals for future fertility and parenthood 
to determine their reproductive priorities. Third, the study measures the reproductive 
concerns of transgender adolescents to identify potential barriers to FP in this population. 
Finally, the study details perceived information gaps about reproductive health and 
fertility to identify areas for educational improvement.  
1.2 Terminology 
When referring to gender and sexuality, a wide range of terminology exists (13,19,25–
28). Here we specify the terms and definitions used in this thesis. However, we recognize 
that these terms are continuously changing, and preferences for word choice may vary 
across individuals, cultures, settings, and time.  
Birth-assigned sex —an individual’s designation as male or female—is typically 
made at birth based on the phenotypic appearance of external genitalia or the 
physiological basis of karyotype or hormonal profiles. Intersex, or more recently 
disorders of sex development, may be used for individuals born with anomalies of the sex 
chromosomes, gonads, reproductive tract, or genitalia (27,28). For these individuals, the 
dichotomous designation as male or female may not be clear.   
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Gender identity—an internal, inherent sense of being male, female, somewhere in 
between, both, or neither—may be consistent with or different from birth-assigned sex. 
Cisgender refers to individuals for whom gender identity is congruent with birth-assigned 
sex. Transgender is the umbrella term for those whose gender identity is incongruent 
with the identity typically associated with birth-assigned sex. For example, a transgender 
male identifies as male but is birth-assigned female. Likewise, a transgender female 
identifies as female but is birth-assigned male. Alternative terms for these identities are 
female-to-male (FtM) and male-to-female (MtF), respectively. Gender non-conforming 
individuals have a gender identity that differs from their birth-assigned sex but may be 
more fluid, complex, or less clearly defined than a transgender identity (19). For 
example, gender-nonconforming individuals may experience themselves as a male or 
female only part of the time, as both genders, as neither gender, or as a gender “other 
than” male or female (29). They may refer to themselves as transgender or as gender non-
binary, gender queer, gender fluid, gender creative, or non-cisgender (30). This diversity 
of gender identities promotes the idea that gender identity exists on a spectrum or 
continuum rather than as a set of distinct and fixed identities (6). 
Of note, sexual orientation is distinct from birth-assigned sex and gender identity. 
Sexual orientation signifies an individual’s identity based on emotional, romantic, or 
sexual attraction to another person or group of people. Therefore, any combination of 
birth-assigned sex, gender identity, and sexual orientation may occur in a given 
individual. 
When birth-assigned sex and gender identity differ, a pervasive and ongoing sense 
of distress known as gender dysphoria may result. It is important to note that not all 
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transgender and gender non-conforming individuals experience gender dysphoria. In 
addition, the terminology used to describe this distress has evolved over time. 
Transsexual has been a term historically used to describe individuals whose gender 
identity differed from birth-assigned sex (13,25). Transsexualism was first recognized as 
a diagnostic term in the Diagnostic and Statistical Manual of Mental Disorders, 3rd 
edition (DSM-III) (31). However, critics have noted that the term transsexual fails to 
address the distress associated with cross-gender identification (32). Additionally, 
transsexual is a misnomer, as the incongruence is related to gender identity and not to 
sexuality (13). Therefore the term transsexual was replaced by gender identity disorder 
in the DSM-IV to denote impairment (32) and again by gender dysphoria in the DSM-V 
(Appendix A) to remove the stigma associated with the diagnosis (33). However, 
transsexual is still in use in some medical settings and by organizations such as the 
Endocrine Society and WPATH to refer to those individuals have begun or have 
completed the process of gender transition (10,13,26). For this thesis, we will forego the 
term transsexual and use the umbrella term transgender to include those with gender 
dysphoria who have or have not transitioned.  
Transition or gender affirmation is the complex process of changing one’s social 
or physical characteristics to better align with gender identity (8). Social transition may 
include modifying dress, behavior, or identifying names and pronouns to match gender 
identity. Physical transition, achieved through gender-affirming medical therapy or 
surgery, may enhance social transition by easing the shift to new styles of dress, social 
activities, or legal documentation that may not otherwise be possible (29). WPATH 
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guidelines specify that social transition occur prior to physical transition (13), but some 
individuals may pursue social transition alone.  
1.3 Epidemiology 
1.3.1 Prevalence of transgender identity in adults  
Epidemiologic data on transgender individuals has been difficult to establish. Prior to 
2007, United States census data and national surveys such as the National Health 
Interview Survey did not inquire about transgender identity (34). Most studies relied on 
self-presentation to a healthcare provider (35) or small statewide surveys (36,37). 
Prevalence estimates from these studies likely understate the true population of 
transgender individuals, given widespread social stigma and discrimination (5,29,38), 
misclassification of transgender identity as a sexual orientation rather than gender 
identity (39), and non-representative sampling.  
More recent analyses of larger population-based studies have suggested that the 
prevalence of transgender adults in the United States is between 0.39% and 0.60%, or 1 
to 1.4 million adults (1,34). A slight majority of transgender adults identify as MtF, with 
the remaining population identifying as either FtM or gender non-conforming (39,40).    
1.3.2 Prevalence of transgender identity in children and adolescents 
Children may present with gender non-conforming or cross-gender behavior in early 
toddlerhood as early as age two (41). Holt et al. studied the demographics of 218 children 
with gender dysphoria who presented for specialized care in the United Kingdom. Most 
gender dysphoric children recognized that their gender identity was different from their 
birth-assigned sex by age 6 and almost all by age 12 (42). Similarly, Olson et al. found 
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that the majority of 101 transgender youth realized their gender incongruence by eight 
years old (2). The average age of presentation is broad, ranging from 8.3 to 19 years old 
(2,42,43), and may reflect differences in access to gender-specific care and cultural 
acceptance.  Since the early 2000s, the number of referrals to specialized pediatric gender 
clinics has drastically increased  (11,21–24). It is possible that the increase in referral 
rates reflects a true increase in the prevalence of gender dysphoria; however, the rapidity 
of this increase in referral rates more likely indicates widening social acceptance and 
access to information on the part of patients (23,24) and expanded recognition and 
clinical interest in treating gender dysphoria on the part of providers (21,22).     
Of the sparse epidemiological data available, the overall prevalence of 
transgender and gender non-conforming identity seems to decrease over the lifespan, with 
the highest rate in childhood and lowest rate in adulthood. A large study of 879 children 
from the general Dutch population reported a 5.8% prevalence of gender variant 
behavior, including behaving like the opposite sex or wishing to be of the opposite sex 
(44). The prevalence is even lower in adolescents than in children. Almeida et al. found 
that 1.4% of 1032 high-school students in Boston considered themselves to be 
transgender (45). Similarly, Clark et al. reported that 1.2% of 8166 high-school students 
in New Zealand identified as transgender. Interestingly, 2.5% of students were unsure 
about their gender (46).  
This data suggests gender dysphoria or gender variant behavior in children will 
most often resolve by adolescence, obviating the need for transition. Reported rates of 
persistence of gender dysphoria from childhood to young adulthood have been low, 
ranging from 12 to 27% (43,47–49). Long-term follow-up of children with gender variant 
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behavior has suggested that this behavior in childhood is a stronger indicator of same-sex 
sexual orientation than of transgender identity (43,44,48). 
Children whose feelings of gender dysphoria persist in adolescence are more likely 
to experience continued gender dysphoria and pursue transition. Few prospective studies 
are available, but de Vries and colleagues longitudinally followed a cohort of 70 gender 
dysphoric patients from adolescence into young adulthood. The cohort was assessed in 
early adolescence at the start of puberty suppression medication, in middle adolescence at 
the start of GAH, and, for a subset of 55 patients, in young adulthood one year after 
gender reassignment surgery (50,51). Only one patient in the cohort of 70 dropped out of 
care, and two refused continued participation, suggesting an almost complete rate of 
persistence of gender dysphoria from adolescence to adulthood. 
1.4 Reproductive Goals and Parenthood Desires 
Many transgender adults are currently parents, and those who are not have high rates of 
desiring parenthood. To determine the prevalence of parenthood in transgender adults, 
Stotzer et al. conducted a systematic review of 51 studies examining transgender 
parenthood. Results from the review indicated that between 25% and 46% of transgender 
adults report being parents (52). For comparison, about 65% of adult males and 74% of 
adult females in the general U.S. population report being biological parents (53). The 
systematic review did not distinguish between biological and non-biological parenthood, 
yet a considerable number of transgender adults favor biological parenthood. A 2017 
U.S. survey found that 50% of 32 transgender adults without children desired biological 
children in the future (54). A cohort of MtF adults in Belgium reported similar results, 
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with 50% of 121 participants disclosing a preference for biologically-related offspring 
(55).  
In contrast to the parenthood goals of transgender adults, the parenthood goals of 
transgender adolescents have been less well described in the literature. Abstracts from 
unpublished studies have provided some insight and have suggested that the goals were 
not necessarily biological parenthood. Clark et al. prospectively surveyed 25 transgender 
adolescents and found that over half strongly desire some form of future parenthood 
(biological or non-biological) (56). Chen et al. surveyed a larger sample of 172 
transgender adolescents online and found that adolescents were almost two times more 
interested in adoption than in biological parenthood (71% vs. 38%) (57). Notably, these 
results were preliminary, and final results have yet to be published.   
The preference of transgender adolescents for non-biological over biological 
parenthood is not surprising. Unlike transgender adults who may have already 
transitioned or may already have children, transgender adolescents focused on 
transitioning may have never considered their attitudes and beliefs about parenthood; 
thus, the idea of having a biological child may be both physically and psychologically 
difficult for an adolescent in this situation. Moreover, transgender individuals are 
encouraged to stop GAH during attempts to conceive and during pregnancy (10,13). 
Stopping GAH may be unappealing because of the development of unwanted secondary 
sexual characteristics and worsening of gender dysphoria. Lastly, the process of sexual 
intercourse and the feminizing experience of pregnancy are, for many, in conflict with 
their gender identity and pose significant barriers to biological parenthood (54).  
 11 
 
1.4.1 Routes to Biological Parenthood 
Transgender adolescents should be informed about the possible effects of GAH 
on fertility and, for those interested in future biological parenthood, about the options 
available for FP and future reproduction. Banking or freezing (also known as 
cryopreservation) of mature oocytes and sperm are the most established and reliable 
methods of FP. Testicular sperm extraction (TESE) followed by sperm banking is 
additional option that has been successfully performed in MtFs at the time of gender-
affirming surgery (58). However, these methods require attainment of puberty for optimal 
results (59). For adolescents who have not completed puberty, ovarian tissue 
cryopreservation (OTC) and testicular tissue cryopreservation are potential routes of 
preserving fertility potential but are still considered experimental in pre- and peri-
pubertal adolescents with immature gametes (60,61). To date, over 60 live births from 
OTC have been reported in cisgender adults after autologous re-implantation of banked 
mature tissue (62,63). However, re-implantation of ovarian tissue may be undesirable for 
FtMs because of the restoration of ovarian activity and resultant increased exposure to 
estrogen. A strategy to avoid ovarian tissue re-implantation would involve the collection 
of oocytes from ovarian tissue, development of the oocytes to maturity in vitro (a process 
known as in-vitro maturation or IVM), and freezing of the mature oocytes. This strategy 
is still in its infancy with few reported cases of success (64,65) and is unlikely to be a 
feasible option for most FtMs currently wishing to preserve fertility.  
After transition, stored gametes can be used in conjunction with assisted 
reproductive technologies (ART) or other fertility services to attempt pregnancy. The 
main form of ART is in vitro fertilization (IVF), in which a retrieved oocyte and sperm 
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are passively combined in a laboratory and the resulting embryo transferred into the 
uterus. IVF may be augmented by intracytoplasmic sperm injection (ICSI), in which the 
retrieved oocyte is injected directly with a sperm and the resulting embryo transferred 
into the uterus. Other assisted fertility options include intrauterine insemination (IUI), in 
which sperm are introduced into the uterus to facilitate fertilization, and third-party 
assisted fertility, such as gamete donation or surrogacy. Light et al. surveyed 41 FtMs 
who experienced pregnancy after transition and found that 20% used ART or other 
fertility services to conceive (66). Similarly, case reports of transgender individuals who 
underwent gamete banking before the start of GAH include descriptions of successful 
pregnancies and live births after unfreezing and ICSI (67,68).  
Transgender individuals on GAH who choose not to undergo FP procedures may 
still experience spontaneous conception. One-fifth of the 41 previously pregnant FtMs in 
the Light study conceived while still amenorrheic (with cessation of menses, in these 
cases after testosterone use), and one-fourth had unplanned pregnancies while taking 
testosterone (66). Thus, testosterone use does not necessarily preclude ovulation and 
pregnancy and should not be considered a contraceptive.  
Indeed, the role of testosterone on fertility in FtMs remains unclear. When 
studying fertility in birth-assigned females, one way to determine ovarian reserve, or the 
remaining supply of oocytes, is by counting the number and type of follicles in each 
ovary. A follicle is the functional anatomical structure within the ovary that contains an 
oocyte as it matures over an ovarian cycle. Several studies have demonstrated normal 
numbers of early follicles in the ovaries of FtMs compared to published cisgender 
controls after more than a year of testosterone therapy, suggesting that GAH has a 
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minimal effect on ovarian reserve (69,70). On the other hand, other studies have found 
that the ovaries of FtMs on long-term testosterone have significantly higher numbers of 
atretic follicles than the ovaries of cisgender controls (71,72). Atretic follicles are those 
that have undergone degeneration and are no longer available for maturation, ovulation, 
and potential fertilization. This process normally occurs with each ovarian cycle but, if 
occurring at an accelerated rate as above, can indicate an increased risk for premature 
ovarian failure and diminished fertility. Because birth-assigned females are unable to 
generate new follicles, this decrease in ovarian reserve is irreversible.    
For MtFs, estrogen has been shown to be associated with impaired fertility. 
Histological studies have shown decreased spermatogenesis—sperm formation and 
maturation—and sperm motility after long-term estrogen therapy (73–75), suggesting that 
GAH decreases the both the number and quality of mature sperm available for 
fertilization. However, the suppressive effect of estrogen on sperm appears to be 
reversible based on available studies, with semen parameters returning to normal within 
three months of GAH cessation (73).     
1.4.2 Fertility Preservation Utilization 
With the advent of new technologies to achieve biological parenthood, an 
increasing number of patients are opting for FP consultation (68,76), while utilization 
rates continue to remain low. Only 3 to 4% of MtF adolescents seen at two specialized 
gender clinics actually completed sperm cryopreservation (77,78). Jones et al. reported 
that nine of eleven MtF adults at a single clinic referred for FP consultation opted for 
sperm cryopreservation, although the total number of MtFs who were seen but declined 
FP consultation was not clear (68). In a survey-based study of 121 MtF adults who had 
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not previously undergone FP, participants reported that their low desire to have sperm 
cryopreserved was due to distress about masturbation to procure a semen sample and 
concern that storage of sperm would inextricably link them to their male identity (55).  
In general, the literature suggests an even lower interest in FP for FtM than for 
MtF patients. Only 37.5% of 50 FtM adults surveyed in Belgium would have preserved 
oocytes during transition, but the technique was not available at the time (79). None of 
three FtM adults in the Jones study chose to undergo oocyte cryopreservation. Similarly, 
none of 23 FtM adolescents at one clinic (77) and only one of six FtM adolescents at a 
105 patient clinic (78) who received fertility counseling elected to undergo oocyte 
cryopreservation. Reasons cited included financial restraint, invasiveness of the oocyte 
retrieval procedure itself, and unwillingness to temporarily stop androgen therapy in 
order to undergo ovarian stimulation (68,78). The findings above suggest that for both 
FtMs and MtFs, FP procedures may be declined largely because they provoke feelings of 
gender dysphoria. However, in adolescents the reasons for FP refusal were obtained 
retrospectively from the few patients who received formal FP counseling; no prospective 
data are available regarding how the general transgender adolescent population 
presenting for care prioritizes their fertility potential and reproductive health.  
1.5 Current Study 
Transgender individuals pursuing transition in adolescence must decide how to reconcile 
this transition with the potential for infertility. Understanding how this reconciliation 
occurs has important clinical implications for the counseling and treatment of adolescents 
with gender dysphoria. Existing literature has focused primarily on patients diagnosed 
with cancer facing gonadotoxic therapies. Adolescents with recent cancer diagnoses and 
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their families rank fertility as a high priority, second only to the achievement of good 
health (80,81), and adult survivors of childhood cancer express regret about missed 
opportunities for FP (82,83). The same reproductive and fertility priorities have not yet 
been established in transgender adolescents. 
Thus, the present study addresses this gap in knowledge by exploring the baseline 
knowledge and attitudes about reproductive health and fertility in transgender youth who 
attend an academic, university-affiliated adolescent gender clinic. A secondary aim is to 
determine which sociodemographic and gender transition factors may affect these 
outcomes. The hypothesis of this study is that most transgender adolescents will desire 
future parenthood but will have low baseline knowledge about transgender fertility 
topics, leading to substantial levels of concern about future reproduction and greater 
perceived information needs. To test this hypothesis, a cross-sectional survey was 
administered over a one-year period to transgender youth at a single university-affiliated 
clinic (the Yale Pediatric Gender Program, or YGP). By comparing survey responses to 
demographic and medical data, the study also investigated differences in responses 
according to different ages and stages of the transition process.  
2 Methods 
This survey is a single-center, cross-sectional study designed to evaluate the fertility-
related experiences of transgender adolescents. The prospective survey was made 
available in a clinical setting during patient appointments at the YGP, a university-
affiliated interdisciplinary clinic with healthcare professionals specializing in child 
psychiatry and pediatric endocrinology and consultants in gynecology and plastic 
surgery. The Human Investigations Committee at Yale University approved this study. 
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We obtained written consent from all adults and written assent and consent from all 
minors and their parents who agreed to participate prior to survey completion. 
2.1 Participants and Recruitment 
Patients were included for study participation if they met the following criteria: (i) self-
identified as transgender or gender non-conforming, (ii) age 12 to 22 years, and (iii) 
presented for gender-affirming medical treatment at the YGP between October 2016 and 
August 2017. The lower age limit of 12 (or grade 6) was the age at which the majority of 
Connecticut schools reported teaching students about sexual education topics (84). 
Patients were excluded from study participation if they identified as cisgender, were not 
between the ages of 12 and 22, or did not respond to the questions being explored. 
The research team identified potential participants from a convenience sample of 
patients attending clinic for routine visits. Patients who met inclusion criteria were 
approached by a member of the research team who was not involved in the patient’s 
clinical care and asked to participate. All patients who agreed to participate signed a 
consent form and completed the survey once, either during their clinic appointment or 
during a separate mental health appointment determining readiness for transition. The 
current standard of care at the YGP consists of the completion of a number of 
standardized questionnaires as well as an individualized interview with a mental health 
professional prior to receiving gender-affirming medical treatment. Thus completing the 
survey concurrently with other questionnaires at a clinic or mental health appointment did 
not detract from patient care.  
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2.2 Data Collection 
2.2.1 Outcome Measures 
General socio-demographic and medical data were obtained from participants’ electronic 
medical record. To assess the fertility-related experiences of adolescents who face 
potential infertility as a result of medical treatments, participants completed a prospective 
survey developed by an interdisciplinary research team. Potential items for the survey 
instrument were adapted from previously published questionnaires validated in the young 
adult oncology population for assessment of fertility desires, concerns, and goals (85–88) 
and were designed to examine factors in four domains: baseline knowledge, attitudes 
toward future parenthood, reproductive concerns, and unmet information needs.  
Baseline Knowledge: To establish information on participants’ baseline 
knowledge of survey topics, participants answered five true/false/unsure items derived 
from the ‘Preserving Reproductive Opportunity After Cancer Treatment’ (PROACT) 
survey (86). The PROACT survey consists of a validated knowledge index evaluating 
comprehension of fertility preservation topics in female oncology patients following 
consultation with an infertility specialist but prior to gonadotoxic medical treatment. 
Topics in our survey included basic comprehension of general reproduction, infertility in 
the general population, the role of physicians in predicting infertility, and the basic 
concept of fertility preservation. An additional question regarding the effects of GAH on 
fertility was added by the research team. Mean total knowledge scores were calculated, 
with one point awarded for each correct response and no points awarded for incorrect or 
unsure responses. Overall each participant received an averaged score between 0 and 5. 
Participants were also asked an investigator-designed question about sources used for 
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information on fertility preservation prior to survey completion and were allowed to 
indicate as many sources as applicable.   
Attitudes toward Future Parenthood: To assess the reproductive desires in our 
patient population, participants were asked two investigator-designed questions. The first 
asked whether future parenthood was important to them (yes, no, or unsure). They were 
also asked to indicate their preferred forms of future parenthood including biological 
parenthood or alternative parenthood such as adoption or fostering.  
Reproductive Concerns: To determine participant concerns about fertility and 
parenthood, seven items were adapted from the Reproductive Concerns after Cancer 
(RCAC) Scale (87,88). This scale measured reproductive concerns in young adult cancer 
survivors across six subscales: fertility potential, partner disclosure, child’s health, 
acceptance, becoming a parent, and personal health. The personal health category in our 
population was modified to include concerns regarding a possible delay in initiation of 
GAH. Participants were asked if they worried about their ability to have a child someday 
(fertility potential), if they worried about telling their potential partner that they may not 
be able to have a child (partner disclosure), if they wondered whether their future child 
would have a high chance of being transgender (child’s health), if they accepted the 
inability to have a child someday (acceptance), if they worried that trying to have a child 
would take too much time and effort and if they felt stressed when thinking about trying 
to have a child (becoming a parent), and if they felt concerned about delaying transition 
one month or more in order to preserve eggs or sperm (delaying transition).  
Responses were rated on a 5-point Likert scale where 1= “strongly disagree” and 
5= “strongly agree.” Mean overall and subscale scores were calculated. Higher mean 
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scores suggested greater reproductive concerns, with mean scores of 0-1.00 indicating 
low concern, 1.01-2.00 slight concern, 2.01-3.00 fair concern, 3.01-4.00 moderate 
concern, and 4.01-4.99 significant concern. 
Unmet Information Needs: To determine perceived information needs in this 
population, we adapted five survey items from Benedict et al. (88), which assessed unmet 
information needs and decisional conflict surrounding fertility preservation in young 
adult cancer survivors following chemotherapy. Participants in our survey indicated 
(yes/no) whether they had as much information as they wanted regarding the risk of 
infertility with GAH, sources of fertility assessment, options for fertility preservation, 
risks and benefits of delaying GAH for fertility preservation, and options for alternative 
family-building. Responses were scored by summing item responses (yes = 0 and 1 = 
no), with total scores ranging from 0-5. Higher total scores suggested greater perceived 
information needs. Additional investigator-initiated questions asked participants about 
preferred resources for receiving additional information.  
2.2.2 Validity 
The survey instrument was assessed for validity, clarity, and ease of application. Content 
experts in pediatric and adolescent gynecology (J.C.)2, reproductive endocrinology and 
infertility (A.K.), and pediatric endocrinology (S.W., S.B., A.P.) reviewed survey 
questions for content validity and item clarity. A non-physician epidemiologist (L.L.) 
with minimal transgender experience further assessed the survey for face validity and 
item clarity. Finally, a child psychiatrist (C.O.) specializing in transgender adolescent 
                                               
2 J.C. = Julia Cron, MD; A.K. = Amanda Kallen, MD; S.W. = Stuart Weinzimer, MD; S.B. = Susan 
Boulware, MD; A.P. = Anisha Patel, DO; L.L. = Lisbet Lundsberg, PhD; C.O = Christy Olezeski, PhD 
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care adjusted the language of the survey instructions and questions to a level appropriate 
to the patient population and provided feedback about the feasibility of survey 
administration in the clinic setting. Minor modifications were made according to the 
reviewers’ recommendations. These recommendations included adding an “unsure” 
category, changing the specialized term “cross-hormone therapy” (now referred to as 
gender-affirming hormones or GAH) to the patient-friendly term “hormones,” changing 
“male” and “female” to the trans-friendly terms “a person born male” and “a person born 
female,” and removing scale numbering to prevent undue influence of scoring on 
participant responses. The final survey consisted of 22 questions across four domains 
detailed above. We did not complete pilot testing with transgender youth prior to survey 
administration because of anticipated small sample size of eligible participants.    
2.3 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism version 7.0c (GraphPad 
Software, La Jolla California, www.graphpad.com). Descriptive statistics were used to 
summarize participants’ baseline characteristics. Frequency and percentage were used for 
categorical data and mean and standard deviation for continuous data.  
Unpaired t-tests and one-way analyses of variance were conducted to assess 
differences in continuous data, including mean scores in baseline knowledge, 
reproductive concern, and unmet information needs. Fisher’s exact test was used to 
determine differences in categorical data, including frequency of demographic data and 
attitudes toward future parenthood. Outcomes were compared across the 
sociodemographic variables of birth-assigned sex, race, insurance status, and age. The 
age groups of 12 to 14, 15 to 17, and 18 to 22 years were selected to represent early, 
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middle, and late adolescence (89). Additional variables included use of puberty blockers 
or GAH. A P value < 0.05 was considered statistically significant for all analyses. 
2.4 Research Team Contributions 
The author (A.A.) was responsible for the study design and implementation; data 
collection and analysis; and drafting of the thesis work. J.C., A.K., and C.O. contributed 
to the study design through critical review of the survey questionnaire, and J.C. and A.K. 
critically reviewed the thesis work for accuracy and intellectual integrity.  
3 Results  
3.1 Participant Characteristics 
Of the 38 eligible patients seen in clinic during the study time period, a total of 23 
transgender adolescents completed the survey (61% participation rate). Seven additional 
patients were ineligible for survey completion due to age less than 12. There were no 
significant differences in socio-demographic data between eligible participants and non-
participants during the study period (all p>0.05, Appendix B). Most participants 
completed the survey at a routine follow-up visit with a median interval between initial 
presentation and survey completion of 5.6 (IQR: 1.2-10.4) months. 
Overall, the mean age of participants was 16.2 ± 2.5 years at the time of survey 
completion (Table 1). Most participants were birth-assigned females (n=17/23, 74%). 
Among those who were birth-assigned females, the majority (n=15/17, 88%) identified as 
FtM with a few (n=2/17, 12%) identifying as gender non-conforming. The remaining 
participants were birth-assigned males who identified as MtF (n=6/23, 26%). Of the 23 
participants, ten (43%) were on a GnRHa for puberty blockade and eight (35%) were on 
 22 
 
GAH at the time of survey completion. Of the participants on GAH, most (n=7/8, 88%) 
were receiving testosterone, and one (n=1/8, 13%) was receiving estrogen. Five 
participants (n=5/23, 22%) were not on any form of medical therapy at the time of survey 
completion. No significant differences existed between birth-assigned females and birth-
assigned males in regard to age, race or ethnicity, insurance status, and use of puberty 
blockers or GAH (all p>0.05, Table 1). 
Table 1. Participant characteristics by birth-assigned sex. 
Sociodemographic and medical data were extracted from patient medical records and compared between 
birth-assigned females and males using the unpaired t-test for continuous variables and Fisher’s exact test 











Age (years), Mean ± SD 
 Initial Presentation 16.0 ± 2.6 16.0 ± 2.2 15.0 ± 3.8 0.44  
 Survey Completion 16.2 ± 2.5 16.0 ± 2.3 16.2 ± 3.2 0.87 
Race/Ethnicity, n(%) 1.00A  
 White/Caucasian 18 (78) 13 (76) 5 (83)  
 Black/African-American 2 (9) 2 (12) 0 (0) 
 Hispanic or Latino 2 (9) 1 (6) 1 (17) 
 Asian 1 (4) 1 (6) 0 (0) 
Insurance, n(%) 1.00 
 Public 8 (35) 6 (35) 2 (33)  
 Private 15 (65) 11 (65) 4 (66) 
Use of Puberty Blockers  
or GAH, n(%) 0.58 
 Yes 18 (78) 14 (82) 4 (66)  
 No 5 (22) 3 (18) 2 (33) 
GAH = gender-affirming hormones (testosterone or estrogen) 
A Caucasian vs. Non-Caucasian 
 
3.2 Baseline Knowledge 
Participants answered a series of five questions assessing their baseline knowledge about 
reproductive health and fertility topics (Table 2), with a mean total knowledge score of 
3.78 ± 0.80 out of 5 possible points (Table 3). Most adolescents had basic knowledge 
about infertility (Q1) and fertility preservation (Q5) and correctly understood that GAH 
may affect fertility (Q2). However, only a slight majority of participants correctly 
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understood how fertilization occurs (Q4), and fewer than half of participants understood 
the limitations of physicians in predicting the effects of GAH on fertility (Q3).  
Table 2. Baseline knowledge questions about reproductive health and fertility 
Participants were asked a series of five true/false/unsure questions to establish baseline knowledge about 
reproductive health and fertility. % correct indicates the percentage of the 23 total participants who 
answered each question correctly.  
  
Over half of participants (n=16/23, 70%) had discussed the impact of GAH on fertility 
and options for FP with someone prior to survey completion. The most common source 
of information was a physician (n=15/23, 65%; Figure 1). The next most common 
sources of information were friends and family (n=12/23, 52%) and online resources 
(n=9/23, 39%). Almost 1/3 of participants (n=7/23, 30%) reported never receiving 
information about fertility topics from any source. Five of these seven participants (71%) 
were either new patients or follow-up patients not receiving gender-affirming medical 
therapy, but two (29%) were follow-up patients on a GnRHa or testosterone at the time of 
survey completion.  
Question Correct Answer % Correct 
Q1. All people who want to become birth parents are able to False 91 
Q2. Hormones may affect a person’s ability to have a child 
in the future 
True 96 
Q3. A doctor can accurately predict the effect that hormones 
will have on a person’s ability to have a child in the future 
False 44 
Q4. An egg from a person born female and a sperm from a 
person born male are needed to make a baby 
True 61 
Q5. Storing eggs or sperm is one way to preserve the ability 





Figure 1. Previous source(s) of information about gender-affirming hormone therapy and fertility 
Participants specified how they previously received information. Percentage over bar indicates the 
proportion of total sample size who had received information from an indicated source. Participants were 
given the option to select as many sources as applicable, so total percentage exceeds 100%.  
We analyzed the difference between knowledge scores among sub-groups to 
determine potential predictors of the knowledge score (Table 3). Participants who had 
discussed GAH and fertility topics with someone prior to survey completion had 
significantly higher scores than those who had no previous discussion (p<0.05). 
Additionally, race approached significance, with Caucasian participants performing better 
than those who were not Caucasian (p=0.06). Other socio-demographic factors, use of 
puberty blockers or GAH, and time between initial presentation and survey completion 













































Table 3. Mean baseline knowledge score by sociodemographic and gender transition variables. 
Mean total knowledge scores were calculated with a maximum total score of 5. Differences in mean total 
knowledge scores were compared by sociodemographic and gender transition variables using analyses of 
variance. N(%) indicates the number and percentage of participants in each participant group. Bolded 
numbers highlight significant differences in mean knowledge score within a participant group.  
Participant Group  N(%)  
Knowledge Score,  
Mean (SD)A P value  
Total Sample 23 (100) 3.78 (0.80) - 
Sociodemographics 
Birth-Assigned Sex 
   Female  










   12 to 14  
   15 to 17  













   Caucasian 










   Public 










Previous discussion about fertility topics 
   Yes 









Time between initial presentation and 
survey completion 
   ≤ 6 months 












Use of Puberty Blockers or GAH  
   Yes 









GAH = gender-affirming hormones (testosterone or estrogen) 
A Maximum score of 5 
 
3.3 Attitudes toward Future Parenthood 
Overall, participants were about equally divided in reporting future parenthood was 
important (n=7/23, 30%), not important (n=9/23, 39%), or undecided (n=7/23, 30%). The 
likelihood of viewing future parenthood as important did not differ significantly across 
sociodemographic or gender transition variables (Table 4, all p>0.05).  
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When asked which type of parenthood they would prefer, participants indicated 
adoption more frequently than all other forms of parenthood (n=16/23, 70%). Birth-
assigned females were significantly more likely to prefer adoption than birth-assigned 
males (p<0.05). After adoption, the most commonly reported preferences for parenthood 
were fostering (n=10/23, 43%), having one’s own biological child (n=5/23, 22%), and 
having a partner’s biological child (n=5/23, 22%). Although surrogacy was endorsed by 
the fewest numbers of participants (n=4/17, 17%), those who preferred surrogacy were 
significantly more likely to be birth-assigned male than birth-assigned female (p<0.05). 
Preferences for type of parenthood did not vary significantly by other socio-demographic 
or gender transition variables (Appendix C, all p>0.05).  
3.4 Reproductive Concerns 
Participants as a whole had a fair level of reproductive concern with a mean total score of 
2.16 ± 0.51 out of a possible 5 points (Table 5). The greatest reproductive concerns were 
related to the postponement of transition and to the process of becoming a parent. For 
example, more than one-third of participants were concerned about delaying their 
transition to undergo fertility preservation (n=8/23, 35%). More than half of participants 
(n =12/23, 52%) reported feeling stressed when thinking about trying to have a child 
someday, and almost one third were concerned about the time and effort involved in 
trying to have a child (n=7/23, 30%).  
The level of concern about the process of becoming a parent differed significantly 
according to desire for parenthood and age. Interestingly, those who did not consider 
future parenthood to be important had the highest level of concern about the process of 
becoming a parent (p<0.0001, Appendix D) and the lowest levels of concern about their 
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fertility potential (p<0.01) and about disclosing potential infertility to their partner (p 
p<0.05). Participants in early adolescence (age 12 to 14) had a significantly higher level 
of concern about becoming a parent than those in middle (age 15 to 17) or late (age 18 to 
22) adolescence (p<0.0001).  
Participants expressed acceptance of possible infertility and had low levels of 
concern about having a child who might be transgender. Level of reproductive concern 
did not differ significantly by birth-assigned sex or by use of puberty blockers or GAH  


















Table 4. Attitudes toward future parenthood.  
Participants indicated the importance of future parenthood (important/not important) and their interest (yes/no) in different forms of biological or non-biological 
forms of parenthood. All values are n(%), or the number and percentage of participants who responded important or yes to each category. A value of 0 means 
that no participant in a given group indicated importance or interest in that category. Differences in frequency of responses were compared by sociodemographic 
and gender transition variables using Fisher’s exact test. P-values are listed in Appendix C. Bolded numbers highlight significantly different frequencies of 
importance/interest within a participant group.  








Bio Child Surrogacy 
 
Adoption Fostering 
Total Sample  7 (30) 5 (22) 5 (22) 4 (17)  16 (70) 10 (43) 
Sociodemographics 
Birth-Assigned Sex 
   Female (N=17) 




















   12 to 14 (N=6) 
   15 to 17 (N=12) 


























   Caucasian (N=18) 




















   Public 




















Use of Puberty Blockers or GAH  
   Yes (N=18) 



















GAH = gender-affirming hormones (testosterone or estrogen) 
A Participants were given the option to select more than one; totals may exceed 100% 







Table 5. Reproductive concerns by participant characteristics. 
Participants ranked how concerned they were about six areas of future reproduction. Answers were scored on a scale from 1 to 5, with 5 indicating the highest 
level of concern. Mean total score was calculated by averaging the scores across all six subscales for each participant. Differences in scores were compared using 
analyses of variance. P values are listed in Appendix D. Mean (SD) are mean scores with standard deviation in parentheses. Bolded numbers highlight 
significantly different levels of concern by analyses of variance within a participant group.  
Participant Group 













Total Sample 1.82 (1.10) 2.04 (1.22) 1.61 (0.94) 1.57 (1.04) 2.61 (1.31) 2.57 (1.65) 2.16 (0.51) 
Parenthood Desires 
Parenthood Important 
   Yes 
   No 































   Female 
   Male 
Age 
   12-14 
   15-17 



















































Use of Puberty Blockers 
or GAH 
   Yes 





























GAH = gender-affirming hormones (testosterone or estrogen) 
* p<0.05 




3.5 Unmet Information Needs 
Out of 23 participants, 10 (44%) expressed a desire for more information about 
fertility topics. Of these 10, five (50%) had previously discussed fertility topics with a 
physician. The most common topics requested were options for fertility preservation 
(n=7/23, 30%) and the risks and benefits of delaying GAH to undergo fertility 
preservation (n=6/23, 26%; Figure 2). A minority of patients reported wanting more 
information about the possible effects of GAH on fertility (n=4/23, 17%). All participants 
(n=23/23, 100%) reported feeling satisfied with the amount of information they had about 
alternative family-building options such as adoption, fostering, or egg/sperm donation. 
Perceived information needs did not differ significantly by socio-demographic, transition 
process, parenthood desire, or reproductive concern variables (Table 6).  
 
Figure 2. Perceived information needs about fertility topics.  
Participants indicated fertility topics about which they would like more information. Percentage over bar 
indicates the proportion of total sample size expressing an information need about the fertility topic shown. 




















































































Table 6. Unmet information needs by participant characteristics.  
Participants were asked whether they had as much information as they would like on five fertility topics. 
Mean total scores were calculated with a maximum total score of 5 for each participant. Differences in 
mean total scores were calculated between variables within participant groups using analyses of variance. 
N(%) indicates the total number and percentage of participants in each participant group.  






Participant Group  N(%)  
Total Unmet Information 
Score, Mean (SD) P value 
Total Sample 23 (100) 0.83 (1.23) - 
Sociodemographics    
Birth-Assigned Sex 
   Female  










   12 to 14  
   15 to 17  













   Caucasian 










   Public 









Transition Process    
Previous discussion about fertility topics 
   Yes 









Time between initial presentation and 
survey completion 
   ≤ 6 months 













Use of Puberty Blockers or GAH 
   Yes 










Parenthood Desires    
Parenthood Important 
   Yes 
   No 












Reproductive Concern    
Level of Concern by Mean Score 
   Low (0-2) 
   Slight Concern (2-3) 















The primary goal of the study was to determine the knowledge and attitudes of 
transgender adolescents at a single center regarding fertility and future parenthood. The 
key findings of the study were as follows: (1) transgender adolescents possess basic 
knowledge about general reproductive health and fertility topics, yet almost half of 
participants incorrectly answered questions about the details of fertilization and the 
ability of physicians to predict the effect of GAH on fertility; (2) only one-third of 
transgender adolescents in our study considered future parenthood to be important. 
Interest in non-biological parenthood (adoption and fostering) was reported more than 
three times as frequently than interest in biological parenthood, particularly among birth-
assigned females; (3) transgender adolescents overall had a fair level of concern about 
future reproduction, most commonly about the postponement of transition to undergo 
fertility preservation procedures and the time, stress, and effort of becoming a parent. 
Significant predictors of higher levels of reproductive concern included early adolescence 
and reporting future parenthood as unimportant; and (4) fewer than half of transgender 
adolescents requested additional fertility-related information, but those who did most 
commonly requested information about the risks and benefits of various fertility 
preservation options.  
4.1 Baseline Knowledge  
Contrary to our a priori hypothesis, we found that transgender adolescents in our clinic 
possess a basic understanding of general and transgender-specific reproductive health and 
fertility topics, as measured by correct responses to survey questions. These findings 
suggest that transgender adolescents understand general fertility topics and are able to 
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participate in making informed decisions about their reproductive health. Researchers 
have demonstrated the opposite in oncology patients, who also face potential infertility as 
the result of their medical therapy. Oncology patients often demonstrate poor 
reproductive health knowledge before (90) and after (91,92) cancer treatment. This lack 
of knowledge has led to poor patient satisfaction (93,94) and anxiety surrounding fertility 
(95). The difference in knowledge outcomes between our study and the oncofertility 
literature is likely due to differences in previous exposure to fertility-related information. 
Many oncology patients recall limited to no previous information about fertility topics 
(85,95), possibly because they are saturated with the amount of new information and the 
stress of a new cancer diagnosis (94,96). Depending on the stage and type of cancer, 
many oncology patients also may not have the time to process threats to their fertility or 
to undergo FP prior to medical treatment. In contrast, the majority (70%) of transgender 
adolescents in our study report receiving previous information about fertility topics, 
which, consistent with the findings of Balthazar et al. (90), was associated with 
significantly higher knowledge scores. Transgender adolescents in general have more 
time than oncology patients do to learn about the effects of treatment on their fertility and 
to make decisions about FP, if desired. Existing practice guidelines for transgender care 
suggest a minimum of three months of psychotherapy or living full-time in the desired 
gender before receiving GAH and a minimum of 12 months of GAH before undergoing 
gender-affirming surgery (10,13).  
 On average, participants in our study answered only one out of five knowledge 
questions incorrectly, with the most commonly missed questions involving the details of 
fertilization (i.e. An egg from a person born female and a sperm from a person born male 
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are needed to make a baby) and the ability of physicians to accurately predict the effects 
of GAH on fertility. Taken together, our findings imply that transgender adolescents 
understand the overarching concepts of GAH and diminished fertility but may need 
additional discussion about the specific details of reproduction and expectations for their 
medical care. That these details of fertilization were unknown and expectations unclear in 
several patients on gender-affirming medical therapy further suggests missed 
opportunities for patient education that should be prioritized in this young population.   
The most common source of information in our study was a physician (65%) or 
family and friends (52%). A much smaller percentage (32%) of participants had 
researched fertility topics online than the percentage of participants (92%) in a similar 
study by Strang et al. (97). The patient population was similar in both studies, but a 
relative paucity of online resources for information about transgender-specific 
reproductive health and fertility is available to the transgender community. Whereas the 
oncology community has a host of online resources supporting fertility planning (e.g., 
FertileHope.org, the Lance Armstrong Foundation/Livestrong, the Susan G. Komen 
Breast Cancer Foundation) (95,98), the transgender community has exceedingly limited 
access to reliable online information. For example, Wu et al. examined the website 
content of 379 fertility clinics listed on the Society for Assisted Reproductive Technology 
database; only 32% of websites had transgender-specific language (99). The lack of 
representation on fertility websites may lead transgender patients to believe that their 
reproductive needs are overlooked, neglected, or actively discriminated against. As a 
result, they may avoid seeking out and receiving appropriate fertility care.  
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A small minority (9%) of participants in our study reported having received no 
previous information about the impact of gender-affirming medical therapy on fertility 
despite receiving a GnRH agonist or testosterone at the time of survey completion. In our 
pediatric gender clinic, we routinely integrate discussions about risks to fertility from 
gender-affirming medical therapy and goals for future parenthood into every patient’s 
readiness evaluation. Patients who express the desire to have future children are offered a 
referral to a reproductive endocrinologist and infertility specialist for further evaluation 
prior to initiating gender-affirming medical therapy. Our results indicate that this model 
of care is effective, as most participants report having fertility-related discussions with a 
YGP provider. It is possible that the few participants on gender-affirming medical 
therapy who reported not receiving this information simply did not recall that fertility 
preservation was discussed during readiness evaluation. The oncofertility literature 
described many young patients who are unable to accurately recall details of their 
medical and treatment history (100) or of fertility discussions with their providers 
(93,95). In a study by Gilleland et al., 41% of adolescent cancer survivors reported being 
unaware of their risks for infertility despite having documented discussions about 
reproductive health risks (101). Moreover, adolescents may prioritize other healthcare 
issues, further inhibiting their ability to retain knowledge about fertility risks. Cancer 
patients and their families prioritize achieving personal health over preserving fertility 
(80,81). Similarly, results from our studies and others (102) suggest that transgender 
patients prioritize their current transition over their future fertility.  
The multidisciplinary nature of gender-affirming care may also complicate 
discussions surrounding reproductive health and fertility. Current Endocrine Society 
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guidelines recommend that gender-affirming care be provided by a multidisciplinary 
team (10), and access to such multidisciplinary clinics specializing in transgender care 
has expanded rapidly in recent years (11,103,104). Transgender adolescents seeking care 
at these clinics may see a wide variety of healthcare providers in the course of their 
transition—including pediatric endocrinologists, mental health providers, urologists 
and/or gynecologists—who may or may not collaborate on patient care. Published 
guidelines emphasize the importance of addressing fertility issues prior to the start of 
GAH, but do not specify under whose purview this discussion should fall (10,13,19). 
Many individual pediatric gender clinics have published information on treatment 
outcomes in their patient population but do not address their strategies for discussing 
reproductive goals and fertility preservation options  (11,22,104). At the YGP, 
discussions about goals for future parenthood, the impact of GAH on fertility, and 
options for fertility preservation routinely take place with all patients at least twice: once 
with the mental health provider during the readiness evaluation, using a standardized 
interview form, and again with the pediatric endocrinologist prior to initiating GAH. 
Patients who desire further information are then referred to a reproductive 
endocrinologist for further discussion and potential planning for FP procedures. An 
alternative approach—one more likely to ensure that fertility-related discussions take 
place across a variety of clinical settings but is far more time-consuming for clinicians—
is to address fertility and reproductive health risks at every patient encounter. Our data 
demonstrates that such discussions effectively increase patients’ fertility knowledge and 
awareness. Repetition of this information over time may be an important factor in the 
prevention of missed opportunities for preservation of fertility potential and future regret.  
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4.2 Attitudes toward Future Parenthood 
Overall, transgender adolescents did not place an emphasis on the importance of future 
parenthood. About one-third indicated that having a child someday was important and 
one-third were unsure. Participants were interested in non-biological forms of parenthood 
such as adoption or fostering three times more frequently than they were interested in 
biological parenthood. This preference for non-biological over biological forms of 
parenthood in transgender adolescents has also been observed in prior studies (56,57). 
For example, the previously discussed study by Strang et al. found that many transgender 
adolescents (56%) expressed a desire for future parenthood (biological or non-
biological), but few (24%) reported that this desire was specific to biological parenthood 
(97). 
Several explanations could be posited for this disinclination toward biological 
parenthood. The first is that adolescents do not prioritize biological parenthood because 
of their young age. This explanation may seem intuitive given that the average age of 
participants in our study was 16 years while the average age of first-time parents in the 
U.S. is 26 years (105). One could surmise that adolescents are too young to care about 
reproductive issues. However, adolescent oncology patients of a similar age have, in 
several studies, stressed the importance of fertility and biological parenthood (81,94). 
These findings imply that factor(s) other than age must also be playing a role in 
transgender adolescents’ seeming lack of interest in biological parenthood.  
We hypothesize that one of these factors is the stigma associated with transgender 
parenthood. This stigma was not specifically explored in our study, but much of the 
literature reports such stigma, including public opposition and scrutiny towards 
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transgender pregnancy and parenthood (106,107), refusal of reproductive services (108), 
and lack of knowledge and understanding by healthcare providers (109,110). Much of 
this stigma stems from the belief that children of transgender parents are negatively 
affected (106,111). While the literature on the long-term well-being of children with a 
transgender parent is sparse, current findings have shown no difference in outcomes. 
Over a 12-year period, Chiland et al. followed 42 children who were conceived via donor 
insemination and raised by an FtM parent and found no difference in development or 
quality of life between children of transgender and cisgender couples (112). In another 
study, academic performance and rates of depression and attention deficit hyperactivity 
disorder were no higher for children with transgender parents than for the general 
population (113). Thus, the stigma surrounding transgender parenthood exists despite 
evidence suggesting normal developmental, quality of life, and psychological outcomes 
for children of transgender parents.   
A second factor affecting parenthood goals may be the gender dysphoria 
associated with achieving biological parenthood. Gender dysphoria as a deterrent to 
biological parenthood is supported by a notable finding from our study—namely, that 
preferences for some forms of parenthood differ significantly by birth-assigned sex. 
Birth-assigned females were most likely to be interested in adoption, whereas birth-
assigned males were most likely to be interested in surrogacy. These results suggest that 
birth-assigned females who identify as male may see pregnancy as incongruent with their 
gender identity. Ellis et al. interviewed eight FtMs who had been pregnant and given 
birth. Several recalled an intense fear prior to conception that pregnancy would mean a 
return to their female identity (109). Similarly, birth-assigned males who identify as 
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female may view conceiving with a partner by insertive intercourse as an unwanted 
experience (54,108). Of note, Nahata et al. found no difference in preference for adoption 
between birth-assigned males and females in a cohort of 72 transgender adolescents.  
However, parenthood preferences of participants in the Nahata study were obtained 
retrospectively and not documented in 26% of the study population. Our study used a 
prospective approach to prompt transgender adolescents about their preferences for future 
parenthood, and all survey participants answered all questions about parenthood 
preference. Therefore, our findings are likely a more accurate reflection of the differences 
in parenthood preference between birth-assigned males and females.   
The aversion that transgender adolescents feel towards the achievement of 
biological parenthood may resolve by adulthood, and transgender adolescents in fact 
acknowledge this possibility (97,102). de Vries et al. described the remittance of gender 
dysphoria and body image dissatisfaction after GAH (51). Therefore, if parenthood 
desires are linked to gender dysphoria, parenthood desires may change over time as 
gender dysphoria decreases. Adult FtMs in long-term relationships who have deliberately 
achieved biological parenthood via sexual intercourse and pregnancy (66,109) or ART 
(67) have described a decrease in gender dysphoria, reporting a newfound connection and 
purpose to their bodies. Taken together, the literature demonstrates that transgender 
adolescents may change their desire for biological parenthood in adulthood after 
transition, when they have stable partnerships and minimal gender dysphoria.  
4.3 Reproductive Concerns 
The present study found that transgender adolescents had fair levels of overall fertility 
concern. Few participants were concerned about the loss of their fertility potential with 
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gender-affirming medical therapy.  Our findings are consistent with those of Lawlis et al., 
who found that only 7% of 118 transgender adolescents expressed concern about fertility. 
Unsurprisingly, fertility was ranked 25th out of 31 possible concerns in the study sample 
(102). In contrast, the oncofertility literature reports high levels of fertility concern in 
adolescents following gonadotoxic therapy (94,101). We hypothesize that the difference 
between fertility concerns in adolescents with gender dysphoria and adolescents with 
cancer, both of whom receive potentially gonadotoxic therapies, reflects several 
differences in their respective medical treatments. One difference includes the urgency 
and timeline of medical intervention. Adolescents with a life-threatening malignancy may 
not have had time to consider their fertility desires or undergo fertility-preserving 
measures prior to starting chemotherapy or radiation. Therefore, their perceived lack of 
control over their fertility may contribute to higher levels of concern. On the other hand, 
transgender adolescents have much more control over the timing of their transition and 
any desired FP procedures. GAH may be delayed until the adolescent feels certain about 
their fertility desires. A larger time period exists for decision-making and fertility-
preserving procedures if desired, thereby possibly leading to less distress about fertility 
potential. A second difference includes the degree of gonadotoxicity between cancer 
therapy and gender-affirming therapy. Adolescents with cancer—particularly those who 
are older, are treated with alkylating agents or irradiation to the abdominal or pelvic 
organs —are significantly more likely than their siblings to experience impaired fertility 
or sterility, or the inability to conceive without the aid of medical intervention, in 
adulthood (114,115). On the other hand, transgender individuals treated with testosterone, 
estrogen, or GnRHa have shown at least partially reversible effects in fertility, with 
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pregnancy FtMs and normal semen parameters in MtFs report after cessation of GAH 
(66,72). The possibility of the restoration of fertility after stopping GAH may lead many 
transgender adolescents to postpone decision-making about future fertility or to feel 
reassured about their fertility potential. Finally, many oncofertility studies focus on 
survivors who have completed treatment and have post-treatment feelings of regret and 
loss with respect to their fertility (87,88,95,101). Our study focuses on transgender 
adolescents who are at the beginning or the middle of transition; low levels of fertility 
concern may be secondary to motivation to complete transition.  
In fact, one of the most commonly endorsed fertility concerns in our study 
included the postponement of transition to undergo FP. More than 1/3 of participants 
were concerned that undertaking FP would delay their transition, similar to findings of 
prior studies in which participants indicated concern about stopping GAH to achieve 
parenthood (54,79,109,116). We found no difference in level of concern based on use of 
gender-affirming medical therapy. That is, participants on GnRH agonists or GAH had 
similar concern about delaying transition to undergo FP as those who were not yet on 
gender-affirming medication. Thus, timely and continued receipt of gender-affirming 
medical therapy may be worth the risk of infertility for many transgender adolescents. 
Notably, and in contrast with our results, Nahata et al. found that only 1.4% of 72 
transgender adolescents declined FP out of concern about delaying GAH. The conflicting 
results likely represent differences in data collection methods. The data from Nahata’s 
study was abstracted in a retrospective manner from patient charts and therefore only 
reflects concerns that were mentioned and documented during routine patient 
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appointments. Had patients been specifically prompted about their concerns as in our 
study, the prevalence of concern about delaying GAH may have been higher.  
Another concern commonly endorsed in our study was the time, stress, and effort 
required to become a parent. This concern was most frequently expressed by participants 
who indicated that future parenthood was unimportant and by participants in early 
adolescence. From this data we hypothesize that concern about the process of becoming a 
parent may deter some transgender adolescents, particularly the youngest patients who 
may overlook future parenthood, from pursuing fertility preserving measures. Therefore, 
young patients who express that future parenthood is unimportant may in fact need the 
most counseling to make a fertility decision that is based on careful consideration rather 
than fear or concern.  
4.4 Unmet Information Needs 
Our data showing that transgender adolescents have a basic understanding of 
reproductive health and fertility topics is consistent with our subsequent data showing 
low levels of perceived information needs. Over half of participants reported that they 
had all of the information they wanted about fertility topics. The level of perceived 
information need did not differ by parenthood desire or reproductive concern. For 
example, participants who did or did not view future parenthood as important or 
concerning felt similarly well informed about fertility topics. Therefore, our findings are 
likely a reflection of participants feeling content about the amount of information they 
have about fertility topics rather than a reflection of disinterest.  
The informational requests most commonly cited in our study included options 
for FP and risks and benefits of delaying GAH to undergo FP. Similar results have also 
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been observed by Light et al. who found that requests for information about fertility 
options persisted even in FtMs who had already experienced pregnancy (66). Thus, FP 
topics are an area ripe for patient education from providers who care for transgender 
patients. The Children’s Hospital of Pennsylvania addressed this specialized need for FP 
education by creating a centralized, hospital-wide FP care team to provide timely and 
comprehensive FP counseling. The team consists of a pediatric oncologist, nurse 
practitioner, and nurse coordinator who initially see all patients referred for fertility 
counseling and scan inpatient and clinic lists for patients who may be at risk for impaired 
fertility. For patients who express interest in pursuing fertility preservation procedures, a 
reproductive endocrinologist, psychologist, general surgeon and urologist facilitate the 
procedures and provide ongoing counseling and support. Part of the counseling process 
includes access to patient-centered educational videos (www.chop.edu/services/fertility-
preservation-program) (117).  
Surprisingly, the majority of our participants expressed interest in adoption or 
fostering, yet none requested more information about alternative family-building options. 
These findings indicate that transgender adolescents in our clinic receive adequate 
information and counseling about non-biological but not biological options for future 
parenthood. When discussing options for reproduction and parenthood in the context of 
gender-affirming medical therapy, healthcare providers must be cognizant not only of the 
developmental age and stage of the patient but also of the unique needs of a patient with a 
transgender identity. Rodriguez-Wallberg et al. examined the experiences of nine FtMs in 
Sweden undergoing FP to achieve biological parenthood. Participants described 
traditional illustrations of women with ovaries as offensive and preferred illustrations of 
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ovaries within a man’s body (118). Recently, trans-friendly figures such as the “Gender 
Bear,” (119) the “Gender Unicorn,” (120) and the “Genderbread Person” (121) have been 
used to explain gender concepts to children. Similar visual aids sensitive to the gender 
identity and developmental needs of transgender adolescents may also be used to explain 
fertility topics.  
4.5 Limitations of the Present Study 
The present study has several limitations. Participants included a small sample of mostly 
birth-assigned females who identify as male (74%). Population-based studies have found 
that slightly more transgender individuals are birth-assigned male than are birth-assigned 
female. The lack of representation of birth-assigned males in our data, though reflective 
of the patient population seen in our clinic, limits the generalizability of our findings to 
the larger transgender population. In addition, most of the published literature on 
transgender reproductive health stratifies participants by gender identity (MtF, FtM, or 
gender non-binary). Our study sample had too few gender non-binary participants to 
assess the data by gender identity. Participants were thus stratified by birth-assigned sex 
rather than by gender identity. Additionally, our study did not include a control group. 
Inclusion of cisgender controls would allow for better identification of the potential 
differences in baseline knowledge and attitudes toward parenthood between transgender 
adolescents and their cisgender peers. Future studies should include a larger sample size 
of both transgender and cisgender adolescents across multiple institutions to yield more 
generalizable conclusions and allow for important comparisons by gender identity in 
future studies.   
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Other limitations are inherent to all cross-sectional survey studies. We were 
unable to provide additional details or clarifications about survey responses, such as how 
much of the concern related to FP or future parenthood was related to cost, or to follow 
participants over time. Additionally, we did not collect information about the relationship 
status of participants, which could have affected outcomes such as parenthood desires or 
fertility concerns. Future studies should collect this information and assess how attitudes 
regarding fertility and future parenthood change over time. 
4.6 Conclusion 
In summary, our work reveals that there are unique fertility-related needs among 
transgender adolescents in our clinic. Participants had basic knowledge about 
reproductive health and transgender-related fertility and were primarily interested in non-
biological parenthood. Although overall reproductive concerns were low, those with the 
greatest levels of reproductive concern also placed the least importance on future 
parenthood. This data suggests that many transgender adolescents may deny the 
importance of future parenthood out of fear or concern. Future educational initiatives 
should focus on the risks for diminished fertility associated with GAH while mitigating 
concerns with information about the options for the preservation of fertility potential and 
pathways to future parenthood. Healthcare providers, as the main source of information 
in this population, are in a unique position to provide this information. Providers should 
assess parenthood desires and fertility concerns at every patient encounter to account for 
changes in priorities and information needs over time. Information gathered from our 
survey can be used to track patient preferences so that, when needed, healthcare providers 
can make timely referrals to fertility specialists and ensure patient satisfaction with 
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treatment decisions. Future studies may further this area of study by exploring the change 
in fertility-related attitudes over time and the role of regret in transgender adolescents 
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Appendix A. DSM-V Diagnostic Criteria for Gender Dysphoria in Adolescents and 
Adults3 
A. A marked incongruence between one’s experienced/expressed gender and 
assigned gender, of at least 6 months’ duration, as manifested by at least two of 
the following: 
1. A marked incongruence between one’s experienced/expressed gender and 
primary and/or secondary sex characteristics (or in young adolescents, the 
anticipated secondary sex characteristics). 
2. A strong desire to be rid of one’s primary and/or secondary sex characteristics 
because of a marked incongruence with one’s experienced/expressed gender 
(or in young adolescents, a desire to prevent the development of the 
anticipated secondary sex characteristics). 
3. A strong desire for the primary and/or secondary sex characteristics of the 
other gender. 
4. A strong desire to be of the other gender (or some alternative gender different 
from one’s assigned gender). 
5. A strong desire to be treated as the other gender (or some alternative gender 
different from one’s assigned gender). 
6. A strong conviction that one has the typical feelings and reactions of the other 
gender (or some alternative gender different from one’s assigned gender). 
B. The condition is associated with clinically significant distress or impairment in 






                                               
3 Note. From the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), Fifth 
edition. Copyright 2013 by the American Psychiatric Association.  
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Appendix B. Baseline Characteristics of Participants and Non-Participants 
 
Sociodemographic variables were extracted from patient medical records and compared between 
participants and non-participants using an unpaired t-test for continuous variables and Fisher’s exact test 





(N=15) P value 
Age (years), mean ± SD 
 Initial Presentation 16.0 ± 2.6 16.3 ± 2.8 0.74 
Birth-Assigned Sex, n(%)  
 Female 17 (74) 12 (80) 1.0 
 Male  6 (26) 3 (20)  
Gender Identity, n(%) 
 Transgender Male 15 (65) 11 (73) 0.59 
 Transgender Female 6 (26) 2 (13)  
 Gender Non-conforming 2(9) 2 (13)  
Race/Ethnicity, n(%)  
 White/Caucasian 18 (78) 8 (53) 0.27A 
 Black/African-American 2 (9) 3 (20)  
 Hispanic or Latino 2 (9) 2 (13)   
 Asian 1 (4) 1 (7)  
Insurance, n(%)  
 Public 8 (35) 5 (33) 1.0 
 Private 15 (65) 10 (67)  
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Sociodemographics 
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     12 to 14 vs. 15 to 17 
















































Use of Puberty Blockers or GAH 













A All values listed are p-values comparing differences in frequency of important or yes responses by variables within participant groups. 
Bold numbers indicate a significant difference of p<0.05. 
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Appendix D. Reproductive Concerns: Sub-group Analyses using Analyses of VarianceA 

































   Female vs. Female 
Age 






























Use of Puberty Blockers or GAH 















GAH = gender-affirming hormones (testosterone or estrogen) 
A All values listed are p-values comparing differences in reproductive concern scores by variables within participant groups.  
Bold numbers indicate a significant difference of p ≤ 0.05. 
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